Søren L Kristensen1, Pardeep S Jhund2, Lars Køber3, Robert S McKelvie4, Michael R Zile5, Inder S Anand6, Michel Komajda7, John G F Cleland8, Peter E Carson9, John J V McMurray10. 1. BHF Cardiovascular Research Centre, University of Glasgow, Glasgow, Scotland, United Kingdom; Department of Cardiology, Gentofte University Hospital, Copenhagen, Denmark. 2. BHF Cardiovascular Research Centre, University of Glasgow, Glasgow, Scotland, United Kingdom. 3. Department of Cardiology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark. 4. Hamilton Health Sciences, McMaster University, Hamilton, Ontario, Canada. 5. Ralph H. Johnsons Veterans Affairs Medical Center and Medical University of South Carolina, Charleston, South Carolina. 6. Division of Cardiology, University of Minnesota, Minneapolis, Minnesota. 7. Université Paris 6 and Hospital Pitié-Salpétrière, Paris, France. 8. Harefield Hospital, Imperial College, London, United Kingdom. 9. Washington DC Veterans Affairs Medical Center and Georgetown University, Washington, DC. 10. BHF Cardiovascular Research Centre, University of Glasgow, Glasgow, Scotland, United Kingdom. Electronic address: john.mcmurray@glasgow.ac.uk.
Abstract
OBJECTIVES: The aim of this study was to investigate N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels and recent heart failure (HF) hospitalization as predictors of future events in heart failure - preserved ejection fraction (HF-PEF). BACKGROUND: Recently, doubt has been expressed about the value of a history of HF hospitalization as a predictor of adverse cardiovascular outcomes in patients with HF and HF-PEF. METHODS: We estimated rates and adjusted hazard ratios (HRs) for the composite endpoint of cardiovascular death or HF hospitalization, according to history of recent HF hospitalization and baseline NT-proBNP level in the I-PRESERVE (Irbesartan in Heart Failure with Preserved systolic function) trial. RESULTS: Rates of composite endpoints in patients with (n = 804) and without (n = 1,963) a recent HF hospitalization were 12.78 (95% confidence interval [CI]: 11.47 to 14.24) and 4.49 (95% CI: 4.04 to 4.99) per 100 person-years, respectively (HR: 2.71; 95% CI: 2.33 to 3.16). For patients with NT-proBNP concentrations >360 pg/ml (n = 1,299), the event rate was 11.51 (95% CI: 10.54 to 12.58) compared to 3.04 (95% CI: 2.63 to 3.52) per 100 person-years in those with a lower level of NT-proBNP (n = 1468) (HR: 3.19; 95% CI: 2.68 to 3.80). In patients with no recent HF hospitalization and NT-proBNP ≤360 pg/ml (n = 1,187), the event rate was 2.43 (95% CI: 2.03 to 2.90) compared with 17.79 (95% CI: 15.77 to 20.07) per 100 person-years when both risk predictors were present (n = 523; HR: 6.18; 95% CI: 4.96 to 7.69). CONCLUSIONS: Recent hospitalization for HF or an elevated level of NT-proBNP identified patients at higher risk for cardiovascular events, and this risk was increased further when both factors were present.
OBJECTIVES: The aim of this study was to investigate N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels and recent heart failure (HF) hospitalization as predictors of future events in heart failure - preserved ejection fraction (HF-PEF). BACKGROUND: Recently, doubt has been expressed about the value of a history of HF hospitalization as a predictor of adverse cardiovascular outcomes in patients with HF and HF-PEF. METHODS: We estimated rates and adjusted hazard ratios (HRs) for the composite endpoint of cardiovascular death or HF hospitalization, according to history of recent HF hospitalization and baseline NT-proBNP level in the I-PRESERVE (Irbesartan in Heart Failure with Preserved systolic function) trial. RESULTS: Rates of composite endpoints in patients with (n = 804) and without (n = 1,963) a recent HF hospitalization were 12.78 (95% confidence interval [CI]: 11.47 to 14.24) and 4.49 (95% CI: 4.04 to 4.99) per 100 person-years, respectively (HR: 2.71; 95% CI: 2.33 to 3.16). For patients with NT-proBNP concentrations >360 pg/ml (n = 1,299), the event rate was 11.51 (95% CI: 10.54 to 12.58) compared to 3.04 (95% CI: 2.63 to 3.52) per 100 person-years in those with a lower level of NT-proBNP (n = 1468) (HR: 3.19; 95% CI: 2.68 to 3.80). In patients with no recent HF hospitalization and NT-proBNP ≤360 pg/ml (n = 1,187), the event rate was 2.43 (95% CI: 2.03 to 2.90) compared with 17.79 (95% CI: 15.77 to 20.07) per 100 person-years when both risk predictors were present (n = 523; HR: 6.18; 95% CI: 4.96 to 7.69). CONCLUSIONS: Recent hospitalization for HF or an elevated level of NT-proBNP identified patients at higher risk for cardiovascular events, and this risk was increased further when both factors were present.
Authors: Andrew P Ambrosy; Ankeet S Bhatt; Dianne Gallup; Kevin J Anstrom; Javed Butler; Adam D DeVore; G Michael Felker; Marat Fudim; Stephen J Greene; Adrian F Hernandez; Jacob P Kelly; Marc D Samsky; Robert J Mentz Journal: Am J Cardiol Date: 2017-04-12 Impact factor: 2.778
Authors: Boback Ziaeian; Paul A Heidenreich; Haolin Xu; Adam D DeVore; Roland A Matsouaka; Adrian F Hernandez; Deepak L Bhatt; Clyde W Yancy; Gregg C Fonarow Journal: JACC Heart Fail Date: 2017-05-10 Impact factor: 12.544
Authors: Meaghan Lunney; Marinella Ruospo; Patrizia Natale; Robert R Quinn; Paul E Ronksley; Ioannis Konstantinidis; Suetonia C Palmer; Marcello Tonelli; Giovanni Fm Strippoli; Pietro Ravani Journal: Cochrane Database Syst Rev Date: 2020-02-27
Authors: Michael R Bristow; Jorge Silva Enciso; Bernard J Gersh; Christine Grady; Madeline Murguia Rice; Steven Singh; George Sopko; Robin Boineau; Yves Rosenberg; Barry H Greenberg Journal: JACC Basic Transl Sci Date: 2016-04
Authors: Emil Wolsk; Brian Claggett; Marc A Pfeffer; Rafael Diaz; Kenneth Dickstein; Hertzel C Gerstein; Francesca C Lawson; Eldrin F Lewis; Aldo P Maggioni; John J V McMurray; Jeffrey L Probstfield; Matthew C Riddle; Scott D Solomon; Jean-Claude Tardif; Lars Køber Journal: J Am Heart Assoc Date: 2017-05-29 Impact factor: 5.501